The team is now expanding data collection to other imaging centers and pursuing international collaborations to strengthen the evidence base and support the eventual development of formal guidance
On the other hand, the clinical trials on semaglutide (Wegovy) for weight loss have been clear: On average, people taking that medication lose 15% of their body weight over 68 weeks compared to 2.4% of body weight in those taking a placebo
Their regenerative properties make them valuable tools in rehabilitation and recovery programs focused on longevity, cellular health, and metabolic support
Energy Boost: Provides a quick and sustained increase in energy levels
Massive Price Disruption: The cost of therapy has plummeted overnight
In summary, GLP-1 & GIP therapy injections offer a powerful approach for weight loss and diabetes management with the potential for significant weight reduction, improved glycemic control, and long-term metabolic wellness
